Catalyst Event
Eli Lilly and Co (LLY) · Other
From KEDI U.S. Medical AI Index (KUSMAI)
4/10/2026, 12:00:00 AM
The U.S. FDA is expected to make an approval decision on orforglipron, Eli Lilly's oral GLP-1 drug for weight loss, by April 10, 2026, expected; medium importance reflects the potential market expansion for obesity treatments.
Korean Translation
미국 식품의약국(FDA)이 일라이 릴리의 경구용 GLP-1 비만 치료제인 올포글리프론에 대한 승인 결정을 2026년 4월 10일까지 내릴 것으로 예상됨.
Related Recent Events
NVIDIA Corporation (NVDA) · Earnings Release
NVIDIA's Q1 2027 earnings release is scheduled for May 20, 2026; Medium importance is assigned as earnings typically drive 5-10% volatility, and analysts forecast an EPS of $1.74-$1.76 estimated.
5/20/2026, 12:00:00 AM
Schrodinger Inc (SDGR) · Earnings Release
First quarter 2026 earnings release scheduled. Analysts forecast an EPS of approximately -$0.56. As a major price catalyst, high importance is expected.
5/6/2026, 12:00:00 AM
Tempus AI Inc (TEM) · Earnings Release
Tempus AI is expected to report its Q1 2026 earnings, with analysts forecasting revenue of approximately $345.40M and a normalized EPS of -$0.19; medium impact expected from quarterly earnings release, scheduled.
5/5/2026, 12:00:00 AM
Hims & Hers Health Inc (HIMS) · Earnings Release
Q1 2026 earnings release and conference call, with low importance estimated due to the routine nature of the announcement, scheduled.
5/5/2026, 12:00:00 AM
Alphabet Inc (GOOGL) · Earnings Release
Alphabet's Q1 2026 earnings release is scheduled; major tech earnings typically cause >=5% price impact, justifying a Medium importance estimate.
4/23/2026, 12:00:00 AM
Intuitive Surgical Inc (ISRG) · Earnings Release
Intuitive Surgical's first-quarter 2026 earnings release is scheduled. I estimate Medium importance as earnings reports typically cause significant price movement, so the event is scheduled.
4/21/2026, 12:00:00 AM